LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (Nasdaq: ALNY) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at email@example.com.
The investigation centers on the October 5, 2016 announcement that Alnylam would discontinue development of revusiran (an investigational RNA interference therapeutic for the treatment of hereditary ATTR amyloidosis with cardiomyopathy) due to patient safety concerns. The Company stated that reports indicated patients taking revusiran in midstage trials had new or worsening complications of the disease. When this news was announced, shares of Alnylam fell in value.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.